Back to search results

Brief Alcohol-focused Intervention for Patients in Opioid Agonist Treatment

This study is testing a brief alcohol treatment called "Brief opioid-informed alcohol treatment" for people who are taking buprenorphine for opioid use disorder and also drink alcohol. This treatment uses ideas from Motivational Enhancement Therapy (MET) and Cognitive Behavioral Therapy (CBT) to help people reduce their alcohol use. To join, you must be 18 or older, taking buprenorphine for at least two weeks, and meet criteria for alcohol use disorder, drinking at least one day a week. The study aims to see if this treatment is practical and acceptable to patients, and if it can help improve alcohol-related outcomes. The results will help decide if a larger study is needed in the future. The study plans to enroll 60 participants, but its current status is unclear.

Study design
This is an interventional study, meaning participants will receive a specific treatment. It plans to enroll 60 participants.
What's involved
Participants will attend weekly in-person sessions for four weeks.
Compensation
Not stated in the trial record.
Follow-up
The acceptability and feasibility of the treatment will be assessed at Week 4 (end of trial).

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07342504

Better Experiences in Substance Treatment: A Brief Alcohol-focused Intervention Tailored for Patients in Opioid Agonist Treatment

Recruiting
NAAges 18+InterventionalTreatment
University of Notre Dame
~60 participants
Updated 2026-06-09 on ClinicalTrials.gov
What's tested:Brief opioid-informed alcohol treatment

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Acceptability of the treatment
Measured over Assessed at Week 4 (end of trial)
+1 more outcome measured

Conditions

Alcohol Use Disorder
Opioid Use Disorder
Alcohol Use
Opioid Use

Explore related trials

Alcohol use disorderOpioid Use Disorder

Where it's being run

1 sites across 1 states
Indiana1

Who to contact

Ryan Carpenter, PhD
[email protected]
+1 574-631-5429
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Participants must be taking prescribed buprenorphine for at least 2 weeks
Participants must be 18 years or older.
Meet DSM-5 criteria for alcohol use disorder (AUD)
Participants must report alcohol use ≥ 1 day/week on average in the past 28 days
Participants must be able to read simple English

Exclusion

Currently receiving formal alcohol use treatment.
Currently experiencing psychosis

What this trial measures

  • Acceptability of the treatmentAssessed at Week 4 (end of trial)

    Acceptability will be assessed with the Satisfaction Questionnaire (CSQ-8), which ranges in scores from 8 to 32 (higher scores indicate higher satisfaction). Treatment satisfaction will be considered acceptable if the number and percentage of subjects who rate their treatment experience in the "satisfactory" or "highly satisfactory" range on the CSQ-8 is ≥ 80%.

  • Feasibility of the treatmentAssessed at Week 4 (end of trial)

    Retention feasibility will be determined by the number and percentage of enrolled participants who complete the four week treatment protocol.